

ROYAL DAMES OF CANCER RESEARCH

Trustee and New Member Private Reception




NSU
Florida


SPRING
2025

HOPE

Blooms

at the NSU Rumbaugh-Goodwin Institute for Cancer Research





NSU RUMBAUGH-GOODWIN INSTITUTE FOR CANCER RESEARCH

MISSION

Through innovative research, we are developing sensitive methods for detection, devising novel strategies for prevention, discovering new drugs for curing cancer, and saving human lives.

SUMMARY

For more than 60 years, NSU's Rumbaugh-Goodwin Institute for Cancer Research (RGI) has led groundbreaking efforts to better understand and treat some of the most aggressive forms of cancer—one of humanity's greatest challenges. With the steadfast support of the Royal Dames of Cancer Research—totaling \$5,685,350 as of March 2025—RGI continues to focus on improving cancer diagnosis, treatment, and prognosis.

RGI's expansive research portfolio includes drug development targeting brain, pediatric, breast, ovarian, lung, and prostate cancers, among others. This issue of the *RGI Research Update* highlights the institute's research activities and milestones between September 2024 and March 2025, including its most promising brain cancer drug discovery to date. Formerly known as F16, the compound has been renamed RD1 in honor of the Royal Dames' enduring and transformative support.




NOVA SOUTHEASTERN UNIVERSITY
Barry and Judy Silverman College of Pharmacy
Rumbaugh-Goodwin Institute for Cancer Research

PARTNERS IN RESEARCH

Collaborating institutions play a vital role in accelerating discoveries, expanding expertise, and driving impactful cancer research forward.

“Mankind is not destined to die from cancer.”





GLIOBLASTOMA PROJECT

In 2007, RGI director Appu Rathinavelu, Ph.D., identified drug targets and small molecule compounds (drugs code named RD1 and JFD) that inhibit cancer growth with low toxicity. The next several years were dedicated, in part, to conducting extensive preclinical testing and developing formulations for RD1 and JFD.

In 2015, Rathinavelu made a breakthrough discovery: intraperitoneally injected RD1 passed through the blood-brain barrier. NSU responded quickly by developing a team of Ph.D.-level technology managers and patent attorneys to design definitive and enabling experiments. Rathinavelu and his research team at RGI spent three weeks at the Mayo Clinic to study their animal models for brain cancer (glioblastoma) research. Upon returning, the RGI team reproduced the Mayo Clinic animal model at the NSU Center for Collaborative Research (CCR) and began experiments. The results from the RGI's RD1 experiments were promising and used to file for worldwide patent protection and publish high-impact papers.

In 2022, RGI began its planning for first in-human phase I clinical trials.

In 2024, NSU initiated discussions with University of Iowa Pharmaceuticals (UI Pharmaceuticals), a clinical research development organization (CRDO), and Charles River Laboratories of Boston, Massachusetts, a contract research organization (CRO), to reformulate and externally validate the clinical use of RD1 for treating glioblastoma.



PRODUCT DEVELOPMENT PLAN

STEP 1

COMPLETE (SUMMER 2025)

Engage UI Pharmaceuticals (CRDO) and Charles River Laboratories (CRO) of Boston, Massachusetts, to develop human formulation for RD1 and conduct safety studies.

STEP 2

DEFINE ROLES AND RESPONSIBILITIES

CRDO charts a clear course for navigating clinical trial planning and administration.

STEP 3

EXECUTE DEVELOPMENT PLAN

- Refine formulation of RD1 as an intravenous (IV) injectable with therapeutic solubility. (CRDO + RGI)
- Conduct confirmation preclinical testing to freeze the formulation. (CRDO + RGI)
- Develop pre-investigational new drug (IND) documents and meet with the Food and Drug Administration (FDA) for a pre-IND meeting. (CRDO or + RGI)
- Manufacture RD1 under good manufacturing practices (GMP). (CRDO)
- Conduct definitive preclinical studies under good laboratory practices (GLP) conditions. (RGI + CRDO)
- Develop documents and apply for IND for phase I clinical trials. (CRDO)
- Secure granted IND. (FDA)
- Establish collaboration and initiate phase I clinical trials. (CRDO)

RGI's patented F16 drug has been renamed as RD1 (Royal Dames 1) in tribute to the philanthropic organization whose investment made this drug discovery possible. RGI is making steadfast efforts to make announcements about new discoveries in the near future.



2023–2025

ADDITIONAL TESTING AND RESEARCH

PEDIATRIC NEUROBLASTOMA

RGI has initiated new research under the leadership of Appu Rathinavelu, Ph.D., RGI director, to find better cures for treating pediatric neuroblastoma. With start-up funding from the National Pediatric Cancer Foundation, RGI initiated testing of four compounds for the treatment of pediatric neuroblastoma, including RD1, JFD, and a new drugs known as RG-7388, SGI-1027, and CM272. Of the five compounds, CM272 seems to be the most potent. Additional tests are being conducted at RGI to validate in vitro findings. Once the in vitro studies are completed, RGI will initiate preclinical evaluations to determine the clinical use of RG-7388, SGI-1027, CM272, as well as some of the analogs of RD1. In February 2024, Rathinavelu and his research team submitted an Invention Disclosure to NSU's Office of Research and Technology Transfer (RTT) regarding the discovery of CM272 and RG-7388 for treating neuroblastoma. This Invention Disclosure is being reviewed by the RTT's internal team, and a determination will be made regarding the filing of a patent application to protect this invention. In October 2024, Rathinavelu and his team submitted a proposal to the Live Like Bella Pediatric Cancer program of the Florida Department of Health and will be requesting \$250,000 in funding for conducting this research. In February 2025, RGI's team submitted another research proposal to the National Cancer Institute (NCI) and requested \$200,000 funding.

OVARIAN CANCER RESEARCH

RGI scientists and graduate students are exploring the feasibility of combining anticancer drugs with MDM2 inhibitors, epigenetic modifiers, and nuclear export signal (NES) inhibitors for treating chemo-resistant ovarian cancer. The researchers are conducting experiments with drug-resistant ovarian cancer cells obtained from England.

MELANOMA PROJECT

The National Cancer Institute estimates more than 900,000 people live with melanoma in the United States. Despite recent advances in melanoma drug discovery, overall survival for patients with late-stage metastatic melanoma averages less than three years.

Under the leadership of RGI's Dmitriy Minond, Ph.D., novel compounds are being tested for the treatment of melanoma. Preliminary findings suggest that some of the molecules discovered by RGI can modulate the spliceosome function in cancer cells, leading to the increase of signaling toward melanoma cells—a response which can be beneficial to patients. Minond's team is conducting research with humanized models for evaluating the possible human use of their experimental drugs.

RECENT GRANT AND PROPOSAL SUBMISSIONS

MELANOMA THERAPY

Sponsor: Florida Department of Health (FDOH) Casey DeSantis Florida Cancer Innovation Fund Grant

Investigator: Dmitriy Minond, Ph.D., associate professor at the NSU Barry and Judy Silverman College of Pharmacy and lead researcher at NSU's RGI

Project: "Pre-clinical studies of spliceosomal immunomodulators in combination with checkpoint inhibitors in humanized melanoma mouse model"—grant amount \$424,289 for one year, April 2025–March 2026

Minond also received the \$573,000 Discovery Science Research Grant from the Bankhead-Coley Cancer Research Program of the Florida Department of Health in 2022, for the initiation of the "Spliceosomal modulation for regulation of melanoma immunogenicity" project, expected to conclude in December 2025.

PEDIATRIC NEUROBLASTOMA TREATMENT


Sponsor: National Cancer Institute (NCI)

Investigators: Appu Rathinavelu, Ph.D., Umamaheswari Natarajan, Ph.D., and Jyotsna Chawla, Ph.D.

Project: "Testing MDM2 and DNMT Inhibitors for Treating Neuroblastoma Using Xenograft Experimental Model"



NOVA SOUTHEASTERN UNIVERSITY
Barry and Judy Silverman College of Pharmacy
Rumbaugh-Goodwin Institute for Cancer Research



MILESTONES

- 7 patents awarded (#1 in NSU)
- 70+ publications
- 120+ presentations
- 150+ undergrad students trained
- 11 Ph.D. students trained
- powerful collaborations with Moffitt, University of Miami, Mayo Clinic, and others
- \$2 million+ in sponsored research
- \$15 million+ in philanthropy connect

NSU RESEARCH AT A GLANCE

- Alternative Therapies for the Treatment of Aging and CNS Neurological Conditions
- Cancer/Anticancer Therapies
- Cancer Biology
- Cervical Cancer and HIV Prevention
- Degenerative and Cognitive Brain Research
- Dental/Oral Cancer
- Developing Targeted Therapies for Sarcomas
- Neuroscience and ALS
- Regenerative Medicine

RESEARCH INQUIRIES

Appu Rathinavelu, Ph.D.

Director, Rumbaugh-Goodwin Institute
for Cancer Research

Barry and Judy Silverman College of Pharmacy
Nova Southeastern University

(954) 262-0411

appu@nova.edu

PHILANTHROPY

Shannon Wayte, CFRE

Executive Director, Advancement
NSU Health

(954) 529-6776

shannon.wayte@nova.edu

TECHNOLOGY TRANSFER

71

Patent
Applications

38

Worldwide
Patents

22

High-Potential
Technologies

CLINICAL RESEARCH

31 Active Clinical Trials

\$14M Clinical Research Awards

SPONSORED PROGRAMS

257 Active Awards

\$165M Active Funding Across 14 Colleges

25-03-056DBB

